Specify a stock or a cryptocurrency in the search bar to get a summary
ValiRx plc
VALValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom. Address: Stonebridge House, England, United Kingdom, CM22 7BD
Analytics
WallStreet Target Price
463.55 GBXP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures VAL
Dividend Analytics VAL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History VAL
Stock Valuation VAL
Financials VAL
Results | 2019 | Dynamics |